Evidence map›Paper›PMID 29642008›Full record

ArticleCell reports2018

Global Cancer Transcriptome Quantifies Repeat Element Polarization between Immunotherapy Responsive and T Cell Suppressive Classes.

Alexander Solovyov, Nicolas Vabret, Kshitij S Arora, Alexandra Snyder, Samuel A Funt, Dean F Bajorin, Jonathan E Rosenberg, Nina Bhardwaj, David T Ting, Benjamin D Greenbaum

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Cell reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04273061 (Canadian Atezolizumab Precision Targeting for Immunotherapy Intervention), which is not on this map. Cited by 67 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed, 2 pooled it
4.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04273061 phase2recruitingnot on this mapstarted 2020, after this paper: background citation

Canadian Atezolizumab Precision Targeting for Immunotherapy Intervention

TypeinterventionalSponsorBritish Columbia Cancer AgencyRan2020 to 2027Enrolled200ConditionsBreast Cancer, Lung Cancer, Gastrointestinal Cancer, Genitourinary CancerArmsAtezolizumab
3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 2 syntheses or guidelines pooled it, 101 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Alexander SolovyovTisch Cancer Institute, Departments of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Oncological Sciences and Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Nicolas VabretTisch Cancer Institute, Departments of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Oncological Sciences and Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Precision Immunology Institute at the Icahn School of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Kshitij S AroraMassachusetts General Hospital Cancer Center, Boston, MA, USA; Department of Pathology and Department of Surgery, Harvard Medical School, Charlestown, MA, USA.
Alexandra SnyderDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Samuel A FuntDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
Dean F BajorinDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
Jonathan E RosenbergDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Nina BhardwajTisch Cancer Institute, Departments of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Oncological Sciences and Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Precision Immunology Institute at the Icahn School of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
David T TingMassachusetts General Hospital Cancer Center, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA.
Benjamin D GreenbaumTisch Cancer Institute, Departments of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Oncological Sciences and Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Precision Immunology Institute at the Icahn School of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: benjamin.greenbaum@mssm.edu.
Icahn School of Medicine at Mount Sinai · USCornell University · USMemorial Sloan Kettering Cancer Center · USCenter for Cancer Research · USHarvard University · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Scientific ReagentsP01CA087497 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI CORDON-CARDO, CARLOS · 2000 to 2021
$35.4M
MSK Paul Calabresi Career Development Award for Clinical OncologyK12CA184746 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Omar Abdel-Wahab, Simon N. Powell · 2015 to 2026
$8.3M
Modulating anti-HIV immunity by plasmacytoid dendritic cellsR01AI081848 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI BHARDWAJ, NINA · 2010 to 2021
$4.5M
NK cell exhaustion in metastatic melanomaR01CA201189 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BHARDWAJ, NINA · 2016 to 2020
$2.1M
NCI NIH HHS K12 CA184746NCI NIH HHS P01 CA087497NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA201189NIAID NIH HHS R01 AI081848
6 · The paper itself

Abstract

It has been posited that anti-tumoral innate activation is driven by derepression of endogenous repeats. We compared RNA sequencing protocols to assess repeat transcriptomes in The Cancer Genome Atlas (TCGA). Although poly(A) selection efficiently detects coding genes, most non-coding genes, and limited subsets of repeats, it fails to capture overall repeat expression and co-expression. Alternatively, total RNA expression reveals distinct repeat co-expression subgroups and delivers greater dynamic changes, implying they may serve as better biomarkers of clinical outcomes. We show that endogenous retrovirus expression predicts immunotherapy response better than conventional immune signatures in one cohort yet is not predictive in another. Moreover, we find that global repeat derepression, including the HSATII satellite repeat, correlates with an immunosuppressive phenotype in colorectal and pancreatic tumors and validate in situ. In conclusion, we stress the importance of analyzing the full spectrum of repeat transcription to decode their role in tumor immunity.

Indexed as

TranscriptomeAntibodies, MonoclonalCluster AnalysisEndogenous RetrovirusesHumansImmunotherapyKaplan-Meier EstimateLong Interspersed Nucleotide ElementsNeoplasmsRepetitive Sequences, Nucleic AcidSequence Analysis, RNAT-Lymphocyte SubsetsAntibodies, Monoclonalcancer immunityERVHSATIIimmunotherapyinnate immunitymicroenvironmentrepetitive elementsRNA-seq

Identifiers

PMID29642008
PMCPMC6016853
OpenAlexW2620917552

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.